Latest news with #Liver
Time of India
25-06-2025
- Health
- Time of India
Fatty Liver Diet: लिवर के लिए सबसे अच्छे और खराब खाने ! Dr. Anjana Kalia
वर्षा दुबे Produced by: | Navbharat Times• 25 Jun 2025, 4:15 pm Fatty Liver Diet: लिवर के लिए सबसे अच्छे और खराब खाने ! Dr. Anjana Kalia
North Wales Chronicle
12-06-2025
- Entertainment
- North Wales Chronicle
Five-star Palé Hall in Bala appoints new head chef
Acclaimed chef Edward Marsh joins Palé Hall, the AA Five Red Star, Relais and Chateaux destination luxury country house hotel, from the Exclusive Collection's Manor House Hotel in Castle Combe, where he climbed from sous chef to head chef. He brings with him a strong culinary pedigree, including his current role as captain of the English National Culinary Team. Blood Orange (Image: Jodi Hinds) Edward will oversee the entire food offering at Palé Hall, from seasonal lunches and afternoon teas to private dining and the hotel's signature tasting menus in the 3 AA Rosette Henry Robertson Dining Room, which also holds a Green Michelin Star for sustainability. Edward has unveiled an elevated new chapter for fine dining at the hotel, rooted in local ingredients and seasonality. Duck Liver (Image: Jodi Hinds) With the launch of refined four and six course tasting menus, and the opening of a new private dining space, 'Hearth', Edward brings a confident and creative culinary vision to the celebrated Welsh destination. Edward said: "Palé Hall is a place of beauty and distinction, and I feel honoured to be shaping its next culinary chapter. Lamb (Image: Jodi Hinds) "The opportunity to develop dishes that reflect the landscape, while working alongside such passionate people, is a real privilege. "Hearth is particularly special to me; it is a space where food and storytelling meet and where our team can create extraordinary, shared experiences for guests." Coinciding with the new menus is the unveiling of Hearth, Palé Hall's newly reimagined private dining room. Once the original kitchen of the house, built in 1871, the space has been artfully restored to its roots. At its centre stands the original cast iron hearth, now complemented by a new cooking station set within the dramatic bay window, designed to host interactive chef's table experiences. Lobster (Image: Jodi Hinds) The room is anchored by a timber dining table that adapts in form, oval for groups up to 16 or circular for more intimate gatherings. A wine display wall completes the space, showcasing a selection of fine wines and incorporating a discreet service counter where a sommelier can prepare and pour wine exclusively for guests dining in Hearth. Chef Edward putting the finishing touches to his lamb dish (Image: Jodi Hinds) For the Henry Robertson Dining Room, a grand, chandelier-lit space, Edward has introduced seasonal tasting menus that celebrate both precision and produce. Guests can now choose between four and six course menus, each dish designed to showcase exemplary technique, thoughtful balance and a deep respect for local, seasonal ingredients. Canapés (Image: Jodi Hinds) Highlights from the current six course tasting menu include dry aged hogget with asparagus and wild garlic, and Oakchurch strawberries with 35 per cent Ivoire chocolate and elderflower. Edward has also introduced a fresh approach to lunch at Palé Hall, offering a shorter seasonal menu to complement the hotel's more formal dinner service. The chef has also added his own creative touch to the afternoon tea.
Yahoo
10-06-2025
- Health
- Yahoo
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program, Indiana University School of Medicine; and Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. The event will highlight results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need. A live question and answer session will follow the formal presentations. About Naga P. Chalasani, MD Naga P. Chalasani, MD completed medical school in India before he moved to the US to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology and as Director of Terance Kahn Liver Research Program at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), Associate Dean for Clinical Research (2017-2020) interim Chair of the Department of Medicine (2020-2021) and Vice President for Academic Affairs at Indiana University Health (2022-2024). He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999 and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 120 and 75,000 citations (as of Feb 2025). He is an elected member of the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP) and the National Academy of Medical Sciences – India (2024). He has mentored over 75 undergraduate and graduate students, medical students, sub-specialty trainees, and junior faculty. Twenty of his mentees are recipients of federal funding (K award, U01, R21, R01, DOD, and VA Merit Review). To honor his contributions and mentorship, Naga P Chalasani Endowed Professor in Gastroenterology and Hepatology has been established at Indiana University School of Medicine in October 2022. About Naim Alkhouri, MD, FAASLD, DABOM Naim Alkhouri, MD, FAASLD, DABOM is the Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH. Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ. Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG). Dr. Alkhouri has been published in over 260 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect', 'look forward', 'believe', 'hope' and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) 620-3186ir@ Investor Relations Contact:Kevin Gardnerkgardner@ Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.
Yahoo
29-05-2025
- Entertainment
- Yahoo
Off the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Chopped Liver
There are spoilers ahead. You might want to solve today's puzzle before reading further! Chopped Liver Constructor: Kareem Ayas Editor: Amanda Rafkin Kareem: Hope this puzzle inspires you to do two things: 1) Add Latvia to your travel bucket list - a country I have always wanted to see, but never had the chance just yet! 2) Add some Bon Jovi to your workout playlist - nothing makes me want to crank the treadmill up to 9.5 like some Bon Jovi. Kane turned 9 years old this month! Here's a picture of him having some birthday steak. Happy Thursday everybody and thanks for solving! IRAN (13A: Modern Persia) It was in 1935 that the Shah of Persia (Reza Shah) requested the country be referred to as IRAN rather than Persia. In 1959, Reza Shah's son decided that the names Persia and IRAN could be used interchangeably in formal correspondence, but IRAN is the name that is generally used for official purposes. ALOO (14A: ___ paratha (potato dish)) ALOO paratha, which is a flatbread with potato filling, is a dish in Indian, Pakistani, and Bangladeshi cuisine. This is my occasional reminder that ALOO is a South Asian term for potatoes, so when a dish in a crossword clue is described as containing potato, the answer may be ALOO. RULE (39A: "You do not talk about Fight Club," e.g.) The first RULE of Fight Club is you do not talk about Fight Club." This line is spoken by the character Tyler Durden (portrayed by Brad Pitt) in the 1999 movie Fight Club. I haven't seen the movie, but that line has made it into mainstream culture, and I knew the answer immediately. O'NEAL (40A: Name on Shaq's jersey) Shaquille O'NEAL whose nickname is Shaq, is a former professional basketball player and a current sports analyst for Inside the NBA. The name O'NEAL has been on a number of teams' jerseys, as during his 19-year NBA career, Shaq played for the Orlando Magic (1992-1996), the Los Angeles Lakers (1996-2004), the Miami Heat (2004-2008), the Phoenix Suns (2008-2009), the Cleveland Cavaliers (2009-2010), and the Boston Celtics (2010-2011). CASS (43A: Mama ___ of the Mamas and the Papas) Mama CASS Elliot (1941-1974) was a member of the folk rock group, The Mamas & the Papas, and also had a successful solo career before she died of heart failure at the age of 32. ADDAMS (48A: Last name of Wednesday, Pugsley and Uncle Fester) The ADDAMS Family is a creation of cartoonist Charles ADDAMS. The ADDAMS Family consists of Morticia and Gomez ADDAMS, their children Wednesday and Pugsley, Uncle Fester, Grandmama, and Cousin Itt. Other characters include a butler named Lurch, Thing (a disembodied hand), Aristotle (Pugsley's pet octopus), Kitty Kat (Morticia's pet lion), and Cleopatra (a carnivorous plant). Cartoons featuring the ADDAMS Family appeared in The New Yorker between 1938 and 1988. There have been four TV show adaptations of the ADDAMS Family. The first three shows, which originally aired in 1964, 1973, and 1992, were all called The ADDAMS Family. In 1998, the fourth TV series about the family premiered, and was titled The New ADDAMS Family. Wednesday ADDAMS received her own TV show on Netflix in 2022; it is appropriately titled Wednesday. LIVIN' ON A PRAYER (53A: 1986 Bon Jovi hit with the lyric "Take my hand, we'll make it, I swear") "LIVIN' ON A PRAYER" was Bon Jovi's second number one hit on the Billboard Hot 100. ("You Give Love a Bad Name" was Bon Jovi's first number one hit.) Thanks for this earworm, puzzle! "Oh, we're half way there / Oh-oh, LIVIN' ON A PRAYER / Take my hand, we'll make it, I swear / Oh-oh, LIVIN' ON A PRAYER..." EURO (58A: Currency used in Estonia and Lithuania) and LATVIA (11D: Country located between Estonia and Lithuania) Estonia, Lithuania, and LATVIA are three of the 20 members of the European Union that have adopted the EURO as their currency. These three countries are located in northern Europe. LATVIA is located south of Estonia and north of Lithuania. Let's do some word capital review while we're at it: The capital of Estonia is Tallinn, the capital of LATVIA is Riga, and the capital of Lithuania is Vilnius. MICE (63A: Cats stereotypically chase them) Fortunately, we have never had MICE in the house we're living in now, so my cat, Willow, has never had the opportunity to chase them. She has to settle for catching the occasional fly. When I first graduated from college, I rented a house that had occasional wildlife visitors – not only MICE, but also bats and raccoons! I remember the first time the cat I had at the time, whose name was Indy, caught a mouse. He woke me up at one in the morning, upset because his mouse friend had stopped playing with him... I have more MICE stories from my time in that house, but they will have to wait for another time. SOUR (7D: ___ Patch Kids) SOUR Patch Kids is a brand of SOUR and sweet gummy candy. ALLEN (9D: British singer Lily with the hit "Smile") Lily ALLEN's music incorporates elements of electro pop, R&B, and reggae. "Smile" is a 2006 single from her debut studio album, Alright, Still. SUSHI (22D: Uramaki or futomaki) Uramaki is a cylindrical style of SUSHI. Two or more fillings are wrapped in nori, and the roll has a layer of rice on the outside. "Uramaki" means "inside out" or "reverse roll" in Japanese, and the SUSHI is named because the nori is inside of the rice. Futomaki is also a cylindrical style of SUSHI, but it usually has nori on the outside. "Futomaki" means "fat roll" in Japanese, and this type of SUSHI is typically 1.5 to 2.5 inches in diameter. FROYO (35D: Dessert portmanteau) FROYO is a portmanteau of "frozen" and "yogurt." AMERICA (41D: Captain ___ (Marvel superhero)) Captain AMERICA, aka Steve Rogers, made his first appearance in the comics in 1940. Captain AMERICA's superpower abilities are a result of being administered a "super-soldier serum" after joining the U.S. Army in World War II. Chris Evans portrays Captain AMERICA in the Marvel Cinematic Universe. ANIMAL (44D: ___ Crossing (video game series)) In the video game series ANIMAL Crossing, players take up residence in a village populated by anthropomorphic animals. As I have mentioned previously, everything I know about ANIMAL Crossing, I have learned from crosswords. ANDES (50D: Mountain range in Peru) The ANDES mountain range runs along the western edge of South America, and is the longest continental mountain range in the world. Seven countries contain part of the ANDES: Argentina, Chile, Bolivia, Peru, Ecuador, Colombia, and Venezuela. LIFE PRESERVER (20A: Buoyant device for staying afloat) LYFT DRIVER (34A: Person making pickups and drop-offs) LIVIN' ON A PRAYER (53A: 1986 Bon Jovi hit with the lyric "Take my hand, we'll make it, I swear") CHOPPED LIVER: The word LIVER has been CHOPPED by each theme answer: LIFE PRESERVER, LYFT DRIVER, and LIVIN' ON A PRAYER. As I have been writing this, I have amused myself by imagining the puzzle asking, "What am I, CHOPPED LIVER?" Yes, puzzle, that is exactly what you are. Fun that we have the LIVER CHOPPED in a variety of ways: LI/VER, L/IVER, and LIV/ER. Thank you, Kareem, for this delightful puzzle. USA TODAY's Daily Crossword Puzzles Sudoku & Crossword Puzzle Answers This article originally appeared on USA TODAY: Crossword Blog & Answers for May 29, 2025 by Sally Hoelscher
Scottish Sun
27-05-2025
- Sport
- Scottish Sun
Real Betis ‘change their badge' for Conference League final against Chelsea due to incredible omen but fans won't see it
Fans all said same thing as they reacted to shock news TIS THE SEASON Real Betis 'change their badge' for Conference League final against Chelsea due to incredible omen but fans won't see it REAL BETIS have jokingly changed their badge for tomorrow's Conference League final against Chelsea. The Spanish club are looking to defy the odds by winning their first-ever European trophy. 3 Real Betis have changed their club badge ahead of the Conference League final against Chelsea 3 The Spaniards have added a BIRD to their crest Credit: X @RealBetis_en Betis are certainly up against it with Chelsea, who started the season as heavy favourites. Enzo Maresca's £1billion squad have only lost once throughout the entire campaign. And many are expecting the Blues to finish the job in Warsaw on Wednesday evening. However, Betis are hoping that a change to their club badge could prove to be a lucky omen. READ MORE IN FOOTBALL DONE DEL Man Utd 'agree Liam Delap deal with personal terms over £30m transfer accepted' Manuel Pellegrini's side jokingly revealed that they had replaced the middle of their crest with a BIRD for the one-off match. They said: 'Presenting our badge for the Conference League final.' Adding a photo of Antony, who has starred on loan from Manchester United, Betis added: 'Year of the Birds. Year of the GOAT.' But the image is not actually going to appear on Betis' kit. BEST FREE BETS AND BETTING SIGN UP OFFERS And instead, the club were drawing inspiration from various cup winners this season, with many boasting a bird on their badge. Liverpool, who boast a Liver bird on their jersey, stormed to title glory in the Premier League. Inside Chelsea's dressing room celebrations after Champions League spot secured 3 CHELSEA VS REAL BETIS - CONFERENCE LEAGUE FINAL STREAM AND TV INFO Newcastle, dubbed the Magpies for obvious reasons, collected their first-ever trophy in the Carabao Cup. While Crystal Palace, who feature an eagle on their crest, lifted the FA Cup against favourites Man City. Even Tottenham, who sport a cockerel, ended their silverware jinx with victory in the Europa League. And fans were quick to react to the banter online. One said: 'That's crazy.' Another declared: 'Let's go bird for bird.' One noted: 'Might support Chelsea with this nonsense.' Another added: 'Sensational.'
